Syndax Pharmaceuticals Inc (SNDX) — SEC Financial Statements & Analysis

Syndax Pharmaceuticals Inc (SNDX) is a pharmaceutical preparations company, incorporated in DE. Syndax Pharmaceuticals Inc trades on Nasdaq as: SNDX. Syndax Pharmaceuticals Inc (SNDX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04. Based on that filing, Syndax Pharmaceuticals Inc carries a market cap of $1.95B, a P/E ratio of -8.81x, a P/B ratio of 128.84x, a P/S ratio of 7.72x, an enterprise value of $1.85B, and an EV/EBITDA multiple of -9.54x. On profitability, it posts an operating margin of -77.05%, a net margin of -87.60%, a Return on Equity (ROE) of -255.93%, a Return on Assets (ROA) of -33.97%, and a Return on Invested Capital (ROIC) of -261.65%. Per share, it reports EPS of $-2.48, diluted EPS of $-2.48, free cash flow per share of $-2.48, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 222.34% year-over-year, net income growth of -34.10% year-over-year, and EPS growth of -36.06% year-over-year. On the balance sheet, it maintains a current ratio of 6.77x, a quick ratio of 6.26x, working capital of $575.36M, a debt-to-equity ratio of 45.60x, a debt ratio of 0.98, an interest coverage ratio of -97085.50x, free cash flow of $-220.64M (TTM), and net debt of $-92.39M. Figures sourced from SEC EDGAR.

Market Cap

$1.95B

P/E TTM

-8.81x

EPS TTM

$-2.48

P/B TTM

128.84x

ROE TTM

-255.93%

ROA TTM

-33.97%

Debt To Equity

45.60x

Free Cash Flow TTM

$-220.64M

Net Revenue TTM Growth 1Y

222.34%

Data as of 2026-06-30 · Source: SEC EDGAR